18 January 2024
Deltex Medical Group plc
("Deltex Medical", the "Company" or the "Group")
Issue of equity to satisfy equity-settled non-executive directors' fees
The Board of Deltex Medical (AIM: DEMG), announces the issue of 49,372,352 new ordinary shares of 1p each in the capital of the Company (the "Ordinary Shares"), at an issue price of 0.17 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 17 January 2024.
The new Ordinary Shares are being issued in order to satisfy the fees of certain current and former non-executive directors for the year ending 31 December 2023 ("Fee Shares"), as has been done in previous years.
A total of 12,941,176 Fee Shares will be issued to former non-executive director Mark Wippell and a total of36,431,176 Fee Shares will be issued to current non-executive directors as set out below:
| | | | Resultant holding post Fee Shares | |
| Director | Current Ordinary Shares held | Fee Shares issued | Ordinary Shares held | As a percentage of the enlarged share capital on Admission |
| Nigel Keen | 332,267,649 | 22,313,529 | 354,581,178 | 18.70% |
| Chris Jones | 6,479,109 | 14,117,647 | 20,596,756 | 1.09% |
Under the contract with Nigel Keen, he or the Company can opt to settle his fees (plus employer's national insurance) by the issue of new ordinary shares at the share price at the time of issue and the same applies to Chris Jones' and Ben Carswell's contracts for up to half of their fees. These share issues are expected to occur on an annual basis when permitted.
Application for admission to trading and total voting rights
Application has been made for 49,372,352 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 24 January 2024 ("Admission").
Following Admission, the Company's issued share capital will comprise 1,896,025,700 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For further information, please contact:
| Deltex Medical Group plc | 01243 774 837 |
| Nigel Keen, Chairman | |
| Andy Mears, Chief Executive | |
| Natalie Wettler, Group Finance Director | |
| | |
| Nominated Adviser and Broker Allenby Capital Limited | 020 3328 5656
|
| Jeremy Porter / Vivek Bhardwaj (Corporate Finance) | |
| Tony Quirke / Stefano Aquilino (Sales & Corporate Broking) | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||
| a) | Name | PDMRs:
| |||||||||
| 2. | Reason for the Notification | ||||||||||
| a) | Position/status | See 1a) above | |||||||||
| b) | Initial notification/Amendment | Initial Notification | |||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a) | Name | Deltex Medical Group Plc | |||||||||
| b) | LEI | 213800XN34P6LI8J6M39 | |||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 0.1p each in Deltex Medical Group Plc
| |||||||||
| Identification code | ISIN: GB0059337583 | ||||||||||
| b) | Nature of the transaction | Fee shares | |||||||||
| c) | Price(s) and volume(s) |
| |||||||||
| d) | Aggregated information: | | |||||||||
| | - Aggregated volume | 36,431,176 | |||||||||
| | - Price | 0.17p | |||||||||
| e) | Date of the transaction | 18 January 2024 | |||||||||
| f) | Place of the transaction | Outside a trading venue | |||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.